Novartis Built a $2 Billion Monopoly in Radioligand Therapy. Telix Just Showed Up.

What Telix Actually Showed (and Didn't)

Let's be precise about what landed at ASCO. Telix presented Part 1 results from ProstACT Global: safety, tolerability, biodistribution, and organ radiation dose estimates from 36 patients across three cohorts. Dr. Pedro C. Barata of University Hospitals Seidman Cancer Center in Cleveland delivered the presentation.

The takeaway? TLX591-Tx appeared safe and tolerable when combined with standard-of-care treatments like enzalutamide, abiraterone, or docetaxel. No unexpected red flags emerged. The dosimetry (how much radiation hits which organs) looked acceptable enough for Telix to advance into Part 2.

What Telix didn't show: any efficacy data. No survival curves. No tumor response rates. No head-to-head comparisons with Pluvicto. The company was explicit about this; efficacy outcomes from the pivotal portion of the trial are still to come.

So this is less "we have a Pluvicto killer" and more "our oven works, and it didn't burn the building down." Important? Absolutely. Definitive? Not even close.

The Road From Here Is Long and Crowded

Part 2 of ProstACT Global is the real test. Roughly 490 patients will be randomized 2:1 to receive TLX591-Tx plus standard of care versus standard of care alone. The primary endpoint is radiographic progression-free survival (basically, how long until scans show the cancer growing again). Overall survival is a key secondary endpoint.

Telix expects primary completion by December 2027, with long-term follow-up running through 2030. That's a long time in a market where Novartis isn't standing still.

Consider the trajectory Pluvicto is on. Its initial approval covered late-line mCRPC (patients who'd already failed hormone therapy and chemotherapy). In early 2025, the FDA expanded the label to pre-chemotherapy mCRPC, roughly tripling the eligible patient pool. Community-setting prescriptions surged 60% in a single quarter after that approval. And Novartis has Phase 3 data (PSMAddition) showing a 28% reduction in the risk of radiographic progression or death when Pluvicto is added to standard treatment in even earlier disease.

By the time Telix could realistically file for approval, Pluvicto may be approved across nearly the entire metastatic prostate cancer spectrum.

A Portfolio Play, Not a Single Bet

Telix isn't putting all its chips on TLX591-Tx. The company is also developing TLX597-Tx, a small-molecule PSMA radioligand (more like Pluvicto's format) that showed encouraging dosimetry at IPCS 2026. Early Phase 2 data suggest it delivers lower radiation doses to salivary glands and kidneys while achieving higher tumor uptake compared to existing radioligands.

The strategic idea: use TLX591-Tx (the antibody) and TLX597-Tx (the small molecule) at different points in the disease, potentially giving doctors more options for sequencing treatments. It's a portfolio approach, and it's smart, because the prostate cancer treatment pathway isn't one decision; it's a series of them over years.

Telix isn't alone in the challenger lane, either. Eli Lilly, Bristol Myers Squibb, and AstraZeneca have all made splashy acquisitions and partnerships in radiopharmaceuticals. Alpha-emitter therapies (a different type of radiation entirely) are advancing in early trials. The cozy monopoly Novartis has enjoyed is about to get very noisy.

The $35 Billion Question

The global radiopharmaceutical market is one of the fastest-expanding segments in all of oncology. There's room for more than one winner.

But winning requires proof. Telix has shown its drug is safe enough to keep testing. That clears a necessary hurdle, and the late-breaking designation at ASCO suggests the scientific community is paying attention. Analysts have slapped a "strong buy" on the stock, treating ASCO 2026 as a thesis-confirming milestone.

Still, the distance between "safe in 36 patients" and "changes how we treat prostate cancer" is enormous. Telix needs Part 2 to deliver on rPFS, ideally with a clean enough safety profile to differentiate from Pluvicto on tolerability. Until then, Novartis keeps its crown, its $2 billion revenue base, and its nearly 600 treatment centers humming.

The pizza shop across the street just turned on the lights. Whether anyone actually walks in depends on what comes out of the oven next.

The FDA Just Killed a Sickle Cell Drug — in Biotech's Hottest Market

Fulcrum Therapeutics' sickle cell drug showed real promise, but the FDA shut it down over cancer fears tied to an entire drug class. The stock cratered 50%, the company's only clinical program vanished, and the implications stretch far beyond one biotech.